BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Small Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2158.56 only $755.50

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,998.74
      -0.38%
      US Tech 100
      20,240.00
      -0.65%
      Dow Jones
      44,722.06
      -0.31%
      Brent Oil
      72.805
      0.18%
      Bitcoin
      96,712.22
      1.12%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. RAPT Therapeutics Inc (RAPT)

      7. RAPT Therapeutics Inc (RAPT) News

      RAPT Therapeutics Inc

      RAPT Therapeutics Inc (RAPT)

      NASDAQ
      1.23
      0.11
      (9.82%)
      Closed November 28 4:00PM
      Delayed by 15 minutes
      1.2005
      -0.0295
      (-2.40%)
      After Hours: 7:21PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      RAPT News

      Official News Only

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 15 2024
      RAPT (9.82%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      November 14 2024
      RAPT (9.82%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 12 2024
      RAPT (9.82%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      August 08 2024
      RAPT (9.82%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      August 08 2024
      RAPT (9.82%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      July 19 2024
      RAPT (9.82%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      May 23 2024
      RAPT (9.82%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      May 23 2024
      RAPT (9.82%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      May 23 2024
      RAPT (9.82%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      May 23 2024
      RAPT (9.82%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      May 23 2024
      RAPT (9.82%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      May 09 2024
      RAPT (9.82%)

      RAPT Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      RAPT under $3
      👍️0
      Monksdream Monksdream 3 months ago
      RAPT new 52 week low
      👍️0
      Monksdream Monksdream 3 months ago
      RAPT new 52 low
      👍️0
      Monksdream Monksdream 4 months ago
      RAPT under $4
      👍️0
      Monksdream Monksdream 7 months ago
      RAPT new 52 week
      👍️0
      Monksdream Monksdream 7 months ago
      RAPT under $10
      👍️0
      tickersym tickersym 9 months ago
      Bargin prices!! Lets go!!
      👍️0
      Stockexpertpro Stockexpertpro 9 months ago
      RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

      https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK
      👍️0
      StockLogistics StockLogistics 2 years ago
      Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

      “8:04a ET 5/23/2022 - Benzinga
      RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

      RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”
      👍️0
      StockLogistics StockLogistics 2 years ago
      12.16 gap fill over the next 14.5 weeks
      👍️0
      StockLogistics StockLogistics 2 years ago
      12.16 gap fill over the next 14.5 weeks
      👍️0
      StockLogistics StockLogistics 2 years ago
      15 weeks to go

      8:04a ET 5/23/2022 - Benzinga
      RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

      Countdown to potential billions in revenue.
      👍️0
      StockLogistics StockLogistics 3 years ago
      A ton of insider buying last week
      👍️0
      StockLogistics StockLogistics 3 years ago
      Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing
      👍️0
      Glider549 Glider549 3 years ago
      It happens,,and more often than not doesn't.
      That's why I'd trim, but leave some on the table.
      👍️0
      weasel4339 weasel4339 3 years ago
      It's way up after hours bud
      👍️0
      Glider549 Glider549 3 years ago
      Can't believe some of you did not take profits near the close.
      Greed will kill ya.
      👍️0
      pennyfinder pennyfinder 3 years ago
      Will do
      👍️0
      weasel4339 weasel4339 3 years ago
      I'll keep n eye out. Let me knoe if u hear something about the price
      👍️0
      pennyfinder pennyfinder 3 years ago
      Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.
      👍️0
      weasel4339 weasel4339 3 years ago
      This considered dilution?
      👍️0
      pennyfinder pennyfinder 3 years ago
      LOL

      https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common
      👍️0
      make it happen make it happen 3 years ago
      Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.
      👍️0
      pennyfinder pennyfinder 3 years ago
      Offering AH or tomorrow pre
      👍️0
      make it happen make it happen 3 years ago
      Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

      Large negative lose percentages across the board on margins.

      Only $0.22 revenue per share

      Cash flow will burn all money before end of year.

      Profitability
      Profit Margin 0.00%
      Operating Margin (ttm) -1,064.70%

      Management Effectiveness
      Return on Assets (ttm) -27.62%
      Return on Equity (ttm) -50.34%

      Income Statement
      Revenue (ttm) 5.33M
      Revenue Per Share (ttm) 0.22
      Quarterly Revenue Growth (yoy) 30.70%
      Gross Profit (ttm) 5.04M
      EBITDA -55.53M
      Net Income Avi to Common (ttm) -56.27M
      Diluted EPS (ttm) -2.29

      Balance Sheet
      Total Cash (mrq) 98.41M
      Total Cash Per Share (mrq) 3.93
      Total Debt (mrq) N/A
      Total Debt/Equity (mrq) N/A
      Current Ratio (mrq) 9.21
      Book Value Per Share (mrq) 3.69

      Cash Flow Statement
      Operating Cash Flow (ttm) -45.66M
      Levered Free Cash Flow (ttm) -23.3M
      👍️0
      StockLogistics StockLogistics 3 years ago
      This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it
      👍️0
      Roadtojourney Roadtojourney 5 years ago
      Not even 6 months old and already offering??
      👍️0
      crudeoil24 crudeoil24 5 years ago
      RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
      👍️0
      crudeoil24 crudeoil24 5 years ago
      42.00 > hod.

      RAPT
      👍️0
      crudeoil24 crudeoil24 5 years ago
      29.01 x 30.00

      RAPT
      👍️0
      crudeoil24 crudeoil24 5 years ago
      Multiple Nasdaq circuit breakers halts today

      RAPT
      👍️0
      crudeoil24 crudeoil24 5 years ago
      7.7M shares trading float >

      RAPT
      👍️0

      Your Recent History

      NASDAQ
      RAPT
      RAPT Therapeutics
      Delayed Upgrade Clock